Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinew PharmaROCO:6634 +0.17%25 Market Cap is NT$4,284.47 Mil as of Aug. 24, 2026. GuruFocus rates ROCO:6634 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Sinew Pharma ranks better than 51.76% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sinew Pharma's share price for the quarter that ended in Jun. 2026 was NT$72.7. Sinew Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 71.29 Mil. Therefore, Sinew Pharma's market cap for the quarter that ended in Jun. 2026 was NT$5,182.71 Mil.
Sinew Pharma's quarterly market cap
declined
from Jun. 2025 (NT$3,558.72 Mil) to Dec. 2025 (NT$2,790.96 Mil) but then
increased
from Dec. 2025 (NT$2,790.96 Mil) to Jun. 2026 (NT$5,182.71 Mil).
Sinew Pharma's annual market cap
declined
from Dec. 2023 (NT$4,825.05 Mil) to Dec. 2024 (NT$3,380.33 Mil) and
declined
from Dec. 2024 (NT$3,380.33 Mil) to Dec. 2025 (NT$2,790.96 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinew Pharma's Enterprise Value for Today is NT$3,301.46 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinew Pharma Market Cap Related Terms
Sinew Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Sinew Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6634 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Sinew Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinew Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinew Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinew Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sinew Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinew Pharma (ROCO:6634) has a Market Cap of NT$4,284.47 Mil as of Aug. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinew Pharma and its competitors. According to the industry distribution chart, Sinew Pharma ranks #686 out of 1422 companies in the Biotechnology industry, placing it in the top 48.2%.
Is Sinew Pharma's Market Cap too high?
Sinew Pharma's current Market Cap is NT$4,284.47 Mil. Based on the distribution chart, Sinew Pharma ranks #686 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinew Pharma ranks #686 out of 1422 companies for Market Cap. This puts Sinew Pharma in the upper half of its industry. The industry median Market Cap is 122.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.31, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinew Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 122.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinew Pharma's current Market Cap is NT$4,284.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current Market Cap of NT$4,284.47 Mil. The current Market Cap is NT$4,284.47 Mil. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current Market Cap is NT$4,284.47 Mil as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score
Get the complete analysis for ROCO:6634
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6634 has been successfully added to your 
